Clinicn Investigator, Assc Prf MGBCI Faculty Solid Tumor MGPO, Mass General Research Institute

Associate Professor of Medicine Harvard Medical School

Associate Physician Medicine-Hematology and Medical Oncology, Massachusetts General Hospital

MMSc 2011

MD UC San Francisco School of Medicine 2005

MS 2002

cervical cancer; crispr; device diagnostics; exosome analysis; extracellular vesicles; holography; liquid biopsy; magnetic nanoparticles; molecular diagnostic techniques; nanomedicine; nanoparticles; nanotechnology; neoplastic cells circulating; ovarian cancer; point-of-care systems; solid tumors; translational research and clinical trials; uterine cancer As Director of the MGH Gynecologic Oncology Program, my research interests are centered on advancing the care and outcomes for women with gynecologic cancers through translational and clinical innovation. My work, as Principal Investigator at the MGH Center for Systems Biology, also integrates cutting-edge nanotechnology and systems medicine principles, aiming to enhance diagnostics and therapeutics for solid tumors. I am committed to and have demonstrated innovation in liquid biopsy technologies, including pioneering extracellular vesicle-based diagnostic platforms that have demonstrated promising applications across high-tech and resource-limited settings. This translational approach extends to integrating artificial intelligence and decentralized diagnostics to improve global cancer care. I offer extensive experience leading a diverse portfolio of forward-thinking clinical cancer trials, collaborating closely with patients to ensure their clinical needs are met while advancing the field. Additionally, my role involves mentoring clinical and research trainees, fostering their professional development, and guiding them as future leaders in oncology. Our cadre of world-class medical, surgical, and radiation oncology providers strive to deliver impactful solutions that advance the gynecologic oncology field and improve patients' lives locally, nationally, and beyond.